Summary
Overview
Work History
Education
Timeline
PUBLICATIONS/PRESENTATIONS/POSTERS
ADDITIONAL EXPERIENCE AND HONORS
background-images

Qi Liu

South San Francisco,USA

Summary

  • Innovative Computational Medicinal Chemist with 7+ years of industrial drug discovery experience
  • Delivered therapeutic candidates across diverse modalities: small-molecule inhibitors, protein degraders, and antibody–drug conjugates (ADCs)
  • Contributed to 5+ discovery programs across multiple stages, applying advanced computer-aided and AI-driven drug design
  • Recognized expert in ADC innovation, including novel payload development, dual-payload architectures, and peptide-based linker/payload optimization
  • Proven leadership in managing project chemistry functions, mentoring junior scientists, and fostering cross-functional collaboration to accelerate program success

Overview

15
15
years of professional experience

Work History

Senior Scientist I/II, Medicinal Chemistry

AbbVie
01.2019 - Current
  • Identified potent, selective binders (e.g., NIK inhibitors, pan‑PI3K/mTOR dual inhibitors) for multiple therapeutic targets using AI/ML‑driven, physics‑based, and cheminformatics platforms, including REINVENT, Schrödinger (Desmond, FEP), MOE, GAMESS (FMO), OpenEye, and Jupyter notebooks in Linux/HPC environments
  • Deep expertise in multi‑parameter optimization (MPO) and property‑driven drug design strategies to enable dose optimization
  • Discovered novel ADC payloads (e.g., pan‑PI3K/mTOR dual inhibitors) and engineered peptide‑based dual‑payload linker–drug scaffolds to deliver deep, durable oncology efficacy
  • Led chemistry functions in 2+ projects, partnering closely with project directors as a key driver in achieving critical milestones across diverse discovery stages, from hit identification through to candidate nomination

Postdoctoral Researcher, Advisor: Chaitan Khosla

Stanford University
01.2017 - 01.2019
  • Designed and synthesized nucleoside mimics as Uridine‑Cytidine Kinase 2 (UCK2) inhibitors for host‑targeting, broad‑spectrum antiviral applications in combination with DHODH inhibitor GSK983
  • Discovered conglobatin‑derived macrocyclic compounds targeting the Hsp90‑Cdc37 protein–protein interaction for potential pancreatic cancer therapeutics
  • Developed and implemented biophysical, biochemical, cellular, and dengue virus replication assays for in‑vitro compound profiling within biosafety Level‑2 laboratory environments

Doctoral Researcher, Advisor: Amos B. Smith, III

Upenn
01.2013 - 01.2017
  • Designed and synthesized psymberin analogs with cancer cell-killing potency in the picomolar range
  • Achieved the first total synthesis of an architecturally complex natural product nahuoic acid, and developed diversity-oriented synthetic approaches to analogs inhibiting epigenetic modifier SETD8
  • Developed a one-flask multicomponent union reaction method based on long-range silyl migrations
  • Co-discovered the first photoredox-catalyzed silyl migration for alkylations and arylation

Undergraduate Researcher, Advisor: Prof. Yue Chen

Nankai University
01.2011 - 01.2012
  • Completed total syntheses and structure–activity relationship (SAR) studies of tetrapeptide microtubule inhibitors (MTi), including tubulysin U and tubulysin V

Visiting Scholar, Advisor: Prof. Neil K. Garg

UCLA
01.2011 - 01.2011
  • Developed cross-coupling reaction method to enable Ni-catalyzed amination of phenol derivatives

Education

Postdoctoral research - Medicinal Chemistry

Stanford University
CA, USA
01.2019

Ph.D. - Organic Chemistry

University of Pennsylvania
PA, USA
01.2017

Bachelor of Science - Pharmacy

Nankai University
Tianjin, China
01.2012

Visiting Scholar - Chemistry

UCLA
CA, USA
01.2011

Timeline

Senior Scientist I/II, Medicinal Chemistry

AbbVie
01.2019 - Current

Postdoctoral Researcher, Advisor: Chaitan Khosla

Stanford University
01.2017 - 01.2019

Doctoral Researcher, Advisor: Amos B. Smith, III

Upenn
01.2013 - 01.2017

Undergraduate Researcher, Advisor: Prof. Yue Chen

Nankai University
01.2011 - 01.2012

Visiting Scholar, Advisor: Prof. Neil K. Garg

UCLA
01.2011 - 01.2011

Visiting Scholar - Chemistry

UCLA

Postdoctoral research - Medicinal Chemistry

Stanford University

Ph.D. - Organic Chemistry

University of Pennsylvania

Bachelor of Science - Pharmacy

Nankai University

PUBLICATIONS/PRESENTATIONS/POSTERS

  • Liu, Q.; Pham, L.; Pan, C.; Wang, J.; Dhami, K.; Li, Y.; Serrill, J.; Kasiappan, R.; DeAnda, F.; Punna, S.; Haelsig, K.; Villath, A.; Gadkari, K.; Rha, G.; Haasch, D.; Lai, A.; Purcell, J.; Wang, X. Discovery of novel pan-PI3K and mTOR dual inhibitors as first-in-class antibody-drug conjugate payloads. AACR abstract submitted.
  • Liu, Q.; Dudnik, A.; Wone, D.; Dhami, K.; DeAnda, F.; Pan, C.; Rivkin, A.; Wang, X. The Design and Optimization of NF-κB-inducing Kinase (NIK) Inhibitors for Treatment of B-cell Malignancies. 2024 Medicinal Chemistry Conference GRC.
  • Liu, Q.; Gupta, A.; Okseli-Armlovich, A.; Qiao, W.; Fisher, R. C.; Smith, M.; Carette, E. J.; Bassik, C. M.; Khosla, C. Enhancing the Antiviral Effectiveness of RNA-Dependent RNA Polymerase Inhibition by Combination with Modulators of Mammalian Pyrimidine Metabolism. Cell Chem. Bio., 2020, 27, 668-677.
  • Okseli-Armlovich, A.; Gupta A.; Jimenez, M.; Auld, D.; Liu, Q.; Bassik, C. M.; Khosla, C. Discovery of Small Molecule Inhibitors of Human Uridine-Cytidine Kinase 2 by High-Throughput Screening. Bioorg. Med. Chem. Lett., 2019, 29, 2559-2564.
  • Liu, Q.; Khosla, C.; Gupta, A. Enhancing the Antiviral Efficacy of RNA Virus Inhibition by Combination with Modulators of Pyrimidine Metabolism. Publication number WO/2021/011572, Publication Date 01/21/2021; International Application No. PCT/US2020/041986, Filing Date 07/14/2020.
  • Liu, Q.; Khosla C. Biochemical characterization of cyclopentenyl uracil analogues: Application in the combination antiviral therapy. Oral Presentation, 258th American Chemical Society National Meeting& Exposition, 2019.
  • Liu, Q.; Deng, Y.; Smith, A. B., III. Total Synthesis of (–)-Nahuoic Acid C1(B1). J. Am. Chem. Soc. 2017, 139, 13668–13671. [One of the JACS most-read articles of the month: highlighted by Synfacts, 2017; 13(12), 1230; Highlighted by organic chemistry portal: https://www.organic-chemistry.org/Highlights/2018/03September.shtm]
  • Deng, Y.; Liu, Q.; Smith, A. B., III. Oxidative [1,2]-Brook Rearrangements Exploiting Single-Electron Transfer: Photoredox-Catalyzed Alkylations and Arylations. J. Am. Chem. Soc. 2017, 139, 9487-9490. [One of the JACS most-read articles of the month; highlighted by Synfacts 2017, 13(10), 1076]
  • Liu, Q.; Deng, Y.; Smith, A. B., III. Studies toward the Total Synthesis of Nahuoic Acids. Oral Presentation, 253rd American Chemical Society National Meeting & Exposition, 2017.
  • Liu, Q.; Chen, Y.; Zhang, X.; Houk, K. N.; Liang, Y.; Smith, A. B., III. Type II Anion Relay Chemistry: Conformational Constraints to Achieve Effective [1,5]-vinyl Brook Rearrangement. J. Am. Chem. Soc. 2017, 139, 8710-8717.
  • Liu, Q.; Smith, A. B., III. Type II Anion Relay Chemistry: Conformational Constraints to Achieve Effective [1,5]-vinyl Brook Rearrangement. Oral Presentation, 252nd American Chemical Society National Meeting & Exposition, 2016.
  • Liu, Q.; An, C.; TenDyke, K.; Cheng, H.; Shen, Y. Y.; Hoye, A. T.; Smith, A. B., III. Design, Synthesis, and Evaluation of Ircinistatin (Psymberin) Analogues: Simplification of the Tetrahydropyran Core and the C(11) Substituents. J. Org. Chem. 2016, 81, 1930–1942.
  • Yang, X.; Dong, C.; Chen, J.; Liu, Q.; Han, B.; Zhang, Q.; Chen, Y. Design, synthesis, and biological activities of triazole tubulysin V analogue. Tetrahedron Lett. 2013, 54, 2986.
  • Yang, X.; Dong, C.; Chen J.; Ding, Y.; Liu, Q.; Ma, X.; Zhang, Q.; Chen Y. Total Synthesis of Tubulysin U and its C- 4 Epimer. Chem. Asian J. 2013, 8, 1213-1222
  • Liu, Q.; Mesganaw, T.; Ramgren, S.; Garg, N. K. Nickel (II)-Catalyzed Amination of Phenol Derivative. Poster and Oral Presentation, UCLA, 2011.

ADDITIONAL EXPERIENCE AND HONORS

Reviewed communications and articles for top-tier chemistry and medicinal chemistry journals, including Tetrahedron, Tetrahedron Lett., Org. Lett., J. Org. Chem., ChemMedChem, and Bioorg. Med. Chem. Lett. (2018–present), Certified in the comprehensive cancer research training by Stanford School of Medicine 2018, Honored with distinguished thesis award by Nankai University 2012

Qi Liu